Boston Scientific BSX Beats Estimates and Authorizes $5B Share Buyback

Key Facts

In a move reflecting the strong financial performance of the healthcare sector, Boston Scientific Corporation reported quarterly earnings and revenue that exceeded analyst expectations. According to reports, the company bolstered investor confidence by authorizing a new $5 billion share buyback program, signaling robust cash flows and optimism regarding future growth.

Despite these positive results, the shareholder base saw a notable shift as E. Ohman J or Asset Management AB reduced its stake in the company by 91.4% during the second quarter. However, the earnings beat and the massive buyback program are viewed as bullish catalysts that outweigh the impact of individual institutional exits.

Regarding stock performance, BSX (trading as 0HOY.L) stood at $50.70 at the close of August 10, 2026. Market participants are currently monitoring broader economic signals, such as the recently released ISM Services PMI which printed at 54.1, indicating continued expansion in non-manufacturing sectors.